Microbot Medical is transitioning from R&D to commercialization with its LIBERTY single-use robotic system for endovascular interventions. I assign MBOT a neutral rating with a 1-year price target of ...

Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 ...

Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 434.50% Upside As of ...

People are slowly making their way back to Chicago offices. As of September, Chicago’s central business district was 63.5% as busy as it was in September 2019, prepandemic, according to Avison Young’s ...

Harel Gadot, CEO of Microbot Medical Inc. (NASDAQ:MBOT), was recently a guest on Benzinga's All Access. Microbot Medical makes the LIBERTY® Endovascular Robotic System, a single-use, fully disposable ...

Between 2013 and 2023, CT imaging utilization within emergency departments increased from 18.7 to 36.5 per 100 Medicare beneficiaries, according to a study published Sept. 30 in Radiology. Here are ...

We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...

MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...

BEIJING, Aug 5 (Reuters) - China's renewable power potential in far-flung provinces is increasingly going unused, official statistics showed on Monday, as the country rushes to build more ...